IP Library Granted Patent US 8,372,619
Granted Patent B2
US 8,372,619 · App. 12/172,963 · Granted Feb 12, 2013

High fidelity restriction endonucleases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,372,619
App. No.
12/172,963
Granted
Feb 12, 2013
Kind
B2
Abstract

Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions include restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor.

Claims (8)

1. A composition comprising a variant Notl restriction endonuclease having reduced star activity wherein the variant Notl polypeptide comprises an amino acid sequence that differs from the amino acid sequence of the parent Notl polypeptide by a mutation at an amino acid position corresponding to 176 of SEQ ID NO:90.

2. The composition of claim 1 , wherein the mutation is K176A.

3. A composition comprising a variant Notl restriction endonuclease having reduced star activity wherein the variant Notl polypeptide comprises an amino acid sequence that differs from the amino acid sequence of the parent Notl polypeptide by a mutation at an amino acid position corresponding to 177 of SEQ ID NO:90.

4. The composition of claim 3 , wherein the mutation is R177A.

5. A composition comprising a variant Notl restriction endonuclease having reduced star activity wherein the variant Notl polypeptide comprises an amino acid sequence that differs from the amino acid sequence of the parent Notl polypeptide by a mutation at an amino acid position corresponding to 253 of SEQ ID NO:90.

6. The composition of claim 5 , wherein the mutation is R253A.

7. A composition comprising a variant Notl restriction endonuclease having reduced star activity wherein the variant Notl polypeptide comprises an amino acid sequence that differs from the amino acid sequence of the parent Notl polypeptide by a mutation at an amino acid position corresponding to 150 of SEQ ID NO:90.

8. The composition of claim 7 , wherein the mutation is K150A.

Assignments (3)
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Sep 27, 2023
From: NEW ENGLAND BIOLABS, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065044/0729 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2008
From: ZHU, ZHENYU; BLANCHARD, AINE; XU, SHUANG-YONG; GUAN, SHENGXI; WEI, HUA; ZHANG, PENGUA; SUN, DAPENG; CHAN, SIU-HONG
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 021576/0858 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2008
From: ZHU, ZHENYU; BLANCHARD, AINE; XU, SHUANG-YONG; GUAN, SHENGXI; WEI, HUA; ZHANG, PENGUA; SUN, DAPENG
To: NEW ENGLAND BIOLABS, INC.
Reel/Frame 021390/0693 →